Evaluation of anti-hypertensive effect of jujube fruit

Not Applicable

• Conditions: Hypertension.; Essential (primary) hypertension

• Registration Number: IRCT20200506047325N1
• Lead Sponsor: Golestan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 48

Inclusion Criteria

120 mmHg < blood pressure < mmHg 160 (Pre- and stage 1 hypertension)
Age over 18, female or male
Voluntary participation and written consent

Exclusion Criteria

Other heart diseases
Secondary blood pressure
Serum Potassium > 5.5 mmol/L or < 3.5 mmol/L
double serum creatinine in the last 6 months
Severe complications of diabetes or serious macrovascular events within 6 months (for example, cerebral hemorrhage, cerebral infarction, or acute myocardial infarction)
Recent infection in the last 4 weeks
Primary or secondary kidney disease (e.g., IgA nephropathy, membranous nephropathy, or lupus nephritis)
Any cancer and malignancy
Severe mental disorder
Pregnant or lactating women or women who are planning to become pregnant or women who are not using appropriate contraceptive methods
Drug allergies or jujube allergies
Participate in other clinical trials
Use of other herbal medicines to control the symptoms of the present disease
History of smoking, drugs
Other conditions that the researchers considered inappropriate in this clinical study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood pressure. Timepoint: 0: Start studying and receiving medication (in person),1: 2 weeks after receiving stage 1 medication (in person), 3: Week 8 End of stage 2 drug treatment course (in person), 4: Week 12 after receiving the drug stage 3 (face-to-face visit), 5: First follow-up - 2 weeks after receiving the drug (week 14) (telephone follow-up), 6: Second follow-up - 4 weeks after receiving the drug (week 16) (face-to-face visit). Method of measurement: Mercury sphygmomanometer.